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Abstract
Background: Antimicrobial resistance mediated by efflux systems is still poorly characterized in Staphylococcus
aureus, despite the description of several efflux pumps (EPs) for this bacterium. In this work we used several
methodologies to characterize the efflux activity of 52 S. aureus isolates resistant to ciprofloxacin collected in a
hospital in Lisbon, Portugal, in order to understand the role played by these systems in the resistance to
fluoroquinolones.
Results: Augmented efflux activity was detected in 12 out of 52 isolates and correlated with increased resistance
to fluoroquinolones. Addition of efflux inhibitors did not result in the full reversion of the fluoroquinolone
resistance phenotype, yet it implied a significant decrease in the resistance levels, regardless of the type(s) of
mutation(s) found in the quinolone-resistance determining region of grlA and gyrA genes, which accounted for the
remaining resistance that was not efflux-mediated. Expression analysis of the genes coding for the main efflux
pumps revealed increased expression only in the presence of inducing agents. Moreover, it showed that not only
different substrates can trigger expression of different EP genes, but also that the same substrate can promote a
variable response, according to its concentration. We also found isolates belonging to the same clonal type that
showed different responses towards drug exposure, thus evidencing that highly related clinical isolates may
diverge in the efflux-mediated response to noxious agents. The data gathered by real-time fluorometric and RT-
qPCR assays suggest that S. aureus clinical isolates may be primed to efflux antimicrobial compounds.
Conclusions: The results obtained in this work do not exclude the importance of mutations in resistance to
fluoroquinolones in S. aureus, yet they underline the contribution of efflux systems for the emergence of high-level
resistance. All together, the results presented in this study show the potential role played by efflux systems in the
development of resistance to fluoroquinolones in clinical isolates of S. aureus.
Background
Staphylococcus aureus infections, particularly those
caused by methicillin-resistant S. aureus (MRSA), pose
serious therapeutic difficulties and are a major concern
in both the nosocomial and community settings. The
use of fluoroquinolones for the effective treatment of
these infections is impaired by the swift emergence of
fluoroquinolone resistance, a trait widely spread among
clinical MRSA strains [1,2].
Fluoroquinolone resistance in S. aureus has been
mainly attributed to mutations occurring in the quino-
lone-resistance determining region (QRDR) of GrlA/
GrlB (topoisomerase IV, encoded by genes grlA/grlB)
and GyrA/GyrB (DNA gyrase, encoded by genes gyrA/
gyrB); which decrease their affinity to the drug [3-5].
However, fluoroquinolone resistance can also be
mediated by drug efflux, a mechanism that is less well
characterized [6].
To date, several efflux pumps (EPs) have been
described for S. aureus, including the chromosomally
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SdrM, as well as the plasmid-encoded QacA/B, QacG,
QacH, QacJ and Smr [7]. Whereas these efflux pumps
show different substrate specificity, most of them are
capable of extruding compounds of different chemical
classes. These features reveal the potential role of EPs in
providing the cell with the means to develop a multi-
drug resistance (MDR) phenotype and consequently sur-
vive in hostile environments.
A variety of methods have been used to identify active
efflux systems in bacteria, such as the use of radiola-
belled substrates, fluorometric assays or the determina-
tion of the minimum inhibitory concentration (MIC) for
different substrates in the presence of compounds
known to modulate the activity of efflux pumps (usually
described as efflux inhibitors, EIs) [8-10]. This work
aimed to assess and characterize the presence of active
efflux systems in clinical isolates of S. aureus using sev-
eral methodologies and to understand their role in the
development of resistance to fluoroquinolones by S. aur-
eus in the clinical setting, since fluoroquinolones are
considered substrates of the majority of the pumps
encoded by the S. aureus chromosome [7].
Results
Detection of active efflux systems by the Ethidium
Bromide (EtBr)-agar Cartwheel (EtBrCW) Method
For this study, we selected all the S. aureus isolates pre-
senting resistance towards ciprofloxacin received by the
Bacteriology Laboratory of one of the largest hospitals
in Portugal during a four months period. These corre-
sponded to a collection of 52 S. aureus isolates.
Efflux activity amongst these 52 ciprofloxacin resis-
tant isolates was assessed by means of a fast and prac-
tical test, the Ethidum Bromide-agar Cartwheel
(EtBrCW) Method that provides information on the
capacity of each isolate to extrude EtBr from the cells
by efflux, on the basis of the fluorescence emitted by
cultures swabbed in EtBr-containing agar plates. Those
cultures showing fluorescence at lower EtBr concentra-
tions have potentially less active efflux systems than
those for which fluorescence is only detected at higher
concentrations of EtBr [11,12]. The application of this
method allowed the selection of 12 S. aureus isolates
showing increased EtBr efflux activity when compared
to the non-effluxing control strain ATCC25923 and to
the efflux-positive control strain ATCC25923EtBr [13].
These 12 isolates were designated EtBrCW-positive
isolates, whereas the remaining 40 isolates were con-
sidered to have no or intermediate efflux activity and
therefore designated as EtBrCW-negative isolates
(Table 1).
Based upon these results, we continued the study by
further analyzing the 12 EtBrCW-positive isolates, as
well as a group of representative 13 EtBrCW-negative
isolates, as controls.
Real-time assessment of efflux activity
In order to characterize the efflux activity of the cells,
we used a semi-automated fluorometric method pre-
viously developed by our group [14], which allows moni-
toring, on a real-time basis, the accumulation of EtBr
inside the bacterial cells, followed by its efflux.
The first step of this technique is to establish the ideal
conditions for EtBr accumulation inside the cells. Thus,
assays were initially performed to determine the EtBr
concentration above which there is detectable accumula-
tion and to select the most effective efflux inhibitor; that
is the EI that promotes the highest EtBr accumulation.
The EtBr accumulation assays showed that the two
groups of isolates previously established by the EtBrCW
Method differed with respect to their capacity to accu-
mulate EtBr, with EtBrCW-negative isolates retaining
more EtBr than the EtBrCW-positive isolates (Figure 1-
A). The same result was observed for the reference
strain ATCC25923. These differences were reflected in
the minimum EtBr concentration required for detectable
accumulation, which was higher for the EtBrCW-posi-
tive isolates. The accumulation assays performed in the
presence of several EIs showed that verapamil was the
most effective in promoting accumulation of EtBr, for
either EtBrCW-positive isolates, EtBrCW-negative iso-
lates or the reference strain (Figure 1-B).
The conditions established by the accumulation
assays were then used to load cells with EtBr and per-
form efflux assays. The assessment of EtBr efflux on a
real-time basis (during a 10 min frame) detected a
considerable difference between EtBrCW-positive iso-
lates, which showed a pronounced efflux pump activ-
ity, with a prompt and significant decrease in
fluorescence and the EtBrCW-negative isolates, that
showed only basal efflux pump activity, similar to the
one presented by the reference strain (Figure 1-C).
These results confirm the presence of increased efflux
activity in the EtBrCW-positive isolates relatively to
the EtBrCW-negative isolates.
Effect of efflux inhibitors on MICs of fluoroquinolones
and EtBr
As expected, since all clinical isolates were selected on
the basis of resistance to ciprofloxacin, they all pre-
sented high MIC values for fluoroquinolones. Neverthe-
less, the majority of the EtBrCW-positive isolates
displayed higher MIC values for the fluoroquinolones
tested and EtBr, whilst the EtBrCW-negative isolates
presented significantly lower values, although some
overlap exists between the two sets of MIC values
(Table 1). The EIs reduced the MIC values for
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lates to the values presented by the EtBrCW-negative
isolates, confirming the presence of an active efflux
component in those isolates (Table 1). The EIs thiorida-
zine (TZ) and chlorpromazine (CPZ) were the most
effective in reducing the MIC values. Verapamil (VER)
and reserpine (RES) showed a smaller or absent inhibi-
tory effect, while carbonyl cyanide m-chlorophenylhy-
drazone (CCCP) showed no effect on the MIC values
for the compounds tested (data not shown). However,
no full reversion of the fluoroquinolone resistance phe-
notype was obtained with any of the EIs tested, suggest-
ing the contribution of other mechanisms to this
resistance, namely, mutations in the target genes.
Screening for mutations conferring fluoroquinolone
resistance
The 25 isolates representing both EtBrCW-positive and
negative isolates were screened for the presence of chro-
mosomal mutations most commonly associated with
fluoroquinolone resistance in S. aureus, namely the ones
occurring in the QRDRs of both grlA and gyrA genes
[3,5,15,16]. All isolates tested carried mutations in grlA
and gyrA related to fluoroquinolone resistance, in six
different combinations at the protein level (Table 1).
The majority of the isolates presented a double muta-
tion in GrlA together with a single mutation in GyrA,
with 12 isolates carrying the GrlA and GyrA mutations
S80Y/E84K and S84L, respectively; three isolates
Table 1 Genotypic and phenotypic characterization of S. aureus clinical isolates
QRDR mutations
b MIC (mg/L)
c
EtBr CIP NOR NAL
Isolate
a PFGE
pattern
GrlA GyrA No + + No + + No + + No + +
EI TZ CPZ EI TZ CPZ EI TZ CPZ EI TZ CPZ
ATCC25923 - WT WT 6.25 0.75 0.75 0.25 0.125 0.125 0.5 0.125 0.125 64 n.d. n.d.
ATCC25923EtBr - WT WT 200 25 12.5 1 0.25 0.25 2 0.25 0.25 64 n.d. n.d.
SM1 A2 S80Y/E84K S84L 16 44 128 32 64 512 128 256 256 64 64
SM10 A4 S80Y/E84K S84L 16 24 128 64 64 512 128 128 128 64 64
SM14 A3 S80Y/E84K S84L 16 44 256 32 128 1024 128 256 256 64 64
SM17 A4 S80Y/E84K S84L 16 44 256 64 64 1024 256 512 256 64 64
SM25 A1 S80Y/E84K S84L 8 2 4 128 32 64 512 64 128 256 32 64
SM27 A4 S80Y/E84K S84L 16 44 256 32 64 512 128 256 256 64 64
SM43 A1 S80Y/E84K S84L 16 24 128 64 64 512 128 128 512 256 64
SM46 A1 S80Y/E84K S84L 16 44 128 64 64 512 128 256 128 64 64
SM47 A1 S80Y/E84K S84L 8 2 4 256 32 64 512 128 256 256 64 64
SM48 A1 S80Y/E84K S84L 8 4 4 256 32 64 512 128 256 256 64 64
SM50 B1 S80F/E84K S84L 8 12 64 16 16 256 32 64 128 64 64
SM52 C1 E84K S84L 16 12 16 8 8 64 32 32 128 32 64
SM2 B2 S80F/E84K S84L 8 22 32 16 16 128 32 32 64 16 64
SM3 E1 S80Y/E84K S84L 1 1 1 16 8 8 64 32 32 64 16 16
SM4 E2 S80F S84L 4 2 1 88 86 43 23 2 6 4 3 2 6 4
SM5 E3 S80Y/E84K S84L 4 2 1 32 16 16 128 64 64 64 32 32
SM6 A5 S80F E88K 4 2 1 16 16 16 64 32 32 64 32 32
SM7 E1 S80F S84L 2 2 1 8 8 4 64 32 32 128 32 64
SM8 A5 S80F E88K 4 2 1 16 8 16 128 64 64 128 32 64
SM12 E1 S80F S84L 2 2 1 16 8 8 64 32 32 128 32 64
SM16 A6 S80F E88K 4 2 1 16 16 16 128 32 64 64 32 64
SM22 A1 S80Y/E84G S84L 8 4 4 128 16 32 512 128 128 64 32 64
SM34 D1 S80F/E84K S84L 4 2 2 64 16 32 64 16 32 32 16 32
SM36 E1 S80F S84L 4 2 2 16 8 8 64 16 32 128 32 64
SM40 E1 S80F S84L 8 4 4 32 32 32 512 128 128 16 8 16
aIsolates in bold correspond to the EtBrCW-positive isolates.
bWT: wild-type; S: serine; F: phenylalanine; E: glutamate; K: lysine; Y: tyrosine; L: leucine; G: glycine.
cValues in bold-type correspond to a MIC decrease of ≥ four-fold in the presence of the efflux inhibitor (EI) in comparison to the values with no EI [10]. The
concentration of each EI used is defined in the Methods section. EtBr: ethidium bromide; CIP: ciprofloxacin; NOR: norfloxacin; NAL: nalidixic acid; TZ: thioridazine;
CPZ: chlorpromazine; n.d.: not determined.
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and one isolate carrying mutations GrlA S80Y/E84G
and GyrA S84L. The other nine isolates screened
showed a single mutation in both GrlA and GyrA, in
three distinct arrangements (Table 1).
The overall analysis of these results reveals a clear dis-
tinction between the EtBrCW-positive and the EtBrCW-
negative isolates, with each group showing a relatively
homogeneous profile, both in terms of efflux capacity
and mutations in the genes related to fluoroquinolone
resistance. In order to test if such homogeneity would
be the result of clonal expansion of specific S. aureus
clones, the isolates were then typed by macrorestriction
analysis.
Macrorestriction analysis
The clonality of the S. aureus clinical isolates was
assessed by pulsed-field gel electrophoresis (PFGE) ana-
lysis of SmaI macrorestriction profiles. According to the
criteria of Tenover et al [17], six clones were found
among the entire collection. The two predominant
clones, A and E, included several sub-clones and
comprised 25 and 18 isolates, respectively. The remain-
ing clones B, C, D and F, were represented by 1 to 6
isolates (representative data is presented in Table 1 and
Figure 2).
Of the 12 EtBrCW-positive isolates, 10 belonged to
clone A, one to clone B and one to clone C. On the
other hand, the 40 EtBrCW-negative isolates included
all isolates from clone E (18 isolates) plus isolates from
clone A (15), clone B (5), clones D and F (1 isolate
each).
Expression analysis of S. aureus efflux pump genes
The presence of EP genes was assessed by PCR. All S.
aureus isolates carried the five chromosomal genes
tested (norA, norB, norC, mepA and mdeA) and one iso-
late, SM52, carried the plasmid encoded smr gene,
whereas no isolate was found to carry the plasmid
encoded qacA/B gene.
To assess the contribution of each individual pump to
the overall efflux activity presented by each strain, ten
isolates representative of each clone or sub-clone (six
EtBrCW-positive and four EtBrCW-negative,) plus
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Figure 1 Real-time EtBr accumulation/efflux for the representative strains ATCC25923 (reference), SM6 (EtBrCW-negative) and SM52
(EtBrCW- positive). Panel A: Assessment of EtBr accumulation. The arrow indicates the EtBr accumulation at the concentration (mg/L)
chosen for the subsequent assays (panels B and C). Panel B: Assessment of EtBr accumulation in the presence of efflux inhibitors. The EIs
were tested at a sub-inhibitory concentration, namely TZ: thioridazine (12.5 mg/L); CPZ: chlorpromazine (25 mg/L); VER: verapamil (200 mg/L)
and RES: reserpine (20 mg/L). The arrow indicates the EtBr accumulation in the presence of the most effective EI for each isolate. Panel C:
Assessment of EtBr efflux. The assays were done in the presence/absence of 0.4% glucose, with or without the EI verapamil (VER) at a sub-
inhibitory concentration of 200 mg/L. The data presented was normalized against the data obtained in conditions of no efflux (absence of
glucose and presence of 200 mg/L of VER).
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Page 4 of 12reference strain ATCC25923 (also EtBrCW-negative),
were selected for expression analysis by RT-qPCR of EP
genes.
When determining the expression level of efflux pump
genes for the clinical isolates in comparison to the refer-
ence strain ATCC25923 in drug-free media, no overex-
pression of these genes was detected (data not shown).
When these clinical isolates and ATCC25923 were
e x p o s e dt oa ne f f l u xp u m ps u b s t r a t e ,e i t h e rc i p r o f l o x a -
cin or EtBr, at ½ their MICs, and gene expression levels
determined against the respective unexposed condition,
overexpression of efflux pump genes was detected in six
clinical isolates, three EtBrCW-negative and three
EtBrCW-positive as well as in the reference strain itself
(Table 2).
The majority of the isolates showed overexpression of
a single efflux pump gene, most frequently, norB or
mdeA. One isolate showed overexpression of two efflux
pump genes (norB/norC) and another one overexpressed
three EP genes (norB/norC/mepA). Overall, isolates
showed to be more responsive to ciprofloxacin. The smr
gene was found to be overexpressed only in the pre-
sence of EtBr, in accordance to the substrate specificity
described in the literature for this pump [18]. These
same agents had a distinct effect on ATCC25923, which
showed significant overexpression of all efflux pump
genes tested in the presence of EtBr, and a higher over-
expression of norB when exposed to ciprofloxacin
(Table 2).
The effect of drug exposure on the expression level of
the efflux pump genes was further explored by increas-
ing the ciprofloxacin concentration to ¾ the MIC. Iso-
lates that showed EP gene overexpression with ½ the
M I Co fc i p r o f l o x a c i ns h o w e de i t h e ra ni n c r e a s ei nt h a t
expression level or the overexpression of additional
genes. For instance, EtBrCW-positive isolate SM50 over-
expressing norB/norC with ½ MIC of ciprofloxacin, now
showed even higher expression of norB (37.05 ± 18.67)
1   2    3    4    5    6   7    8     9  10  11 12 13  14 15  16  17 18  19 20  21 22
339.5 Kb
436.5 Kb
242.5 Kb
145.5 Kb
388 Kb
291 Kb
194 Kb
97 Kb
48.5 Kb
Figure 2 SmaI macrorestriction profiles of S. aureus clinical isolates. Numbers correspond to the following isolates: 1- SM43; 2- SM46; 3-
SM47; 4- SM48; 5- SM22; 6- SM25; 7- SM1; 8- SM14; 9- SM10; 10- SM17; 11- SM27; 12- SM6; 13- SM8; 14- SM16; 15- SM50; 16- SM2; 17- SM52; 18-
SM34; 19- SM36; 20- SM40; 21- SM3; 22- SM4. The arrows show the position and weight of the lambda ladder molecular size marker.
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Page 5 of 12and norC (83.98 ± 19.98) and de novo overexpression of
norA (8.36 ± 4.63) and mepA (45.86 ± 13.86). Likewise,
exposure of the EtBrCW-negative SM2 to higher cipro-
floxacin concentrations resulted in increased levels of
norB expression (4.48 ± 2.48) that was accompanied by
de novo overexpression of norC (5.33 ± 0.73) and mepA
(10.58 ± 0.73).
Discussion
The few studies on efflux among S. aureus clinical iso-
lates use the decrease of antibiotic MICs in the presence
of EIs, particularly reserpine, as indicative of efflux activ-
ity [10]. This approach is laborious and dependent on
the susceptibility of the efflux system(s) to reserpine,
which varies considerably [19]. More recently, Patel and
colleagues have proposed the use of EtBr MICs to iden-
tify S. aureus effluxing strains [20]. This approach has
the advantage of assessing efflux activity using a broad
range efflux pump substrate, EtBr, which is pumped out
by most efflux systems described for S. aureus, and thus,
is an useful marker for the detection of efflux pump
activity [7,12,14,20]. Nevertheless, it is still an indirect
assessment of efflux activity.
In the present study, we have applied two methods for
the direct assessment of efflux activity among a collection
of 52 ciprofloxacin resistant S. aureus clinical isolates,
both also based on EtBr efflux. We first applied the EtBr-
agar Cartwheel Method to select isolates with increased
efflux activity. The presence of increased efflux in the 12
isolates selected was supported by the data collected
from the semi-automated fluorometric method, which
demonstrated that EtBrCW-positive isolates had a higher
efflux activity than the EtBrCW-negative isolates. Thus,
both methods proved to be adequate to assay efflux activ-
ity in S. aureus cells. In particular, the EtBrCW method
p r o v e dt ob eav a l u a b l et o o lf o rt h er a p i ds c r e e n i n go f
efflux pump activity, allowing its application to screen
large collections of clinical isolates. Furthermore, the use
of a broad range efflux pump substrate such as EtBr war-
rants its wider application as compared to the analysis of
EIs effect on MIC values, which can be severely impaired
by the susceptibility of each efflux system to the EI being
used and for which the mechanism of action at the cellu-
lar level remains, in most cases, to be clarified.
In addition, the semi-automated fluorometric method
also allowed the characterization of this efflux activity,
in terms of maximal concentration of EtBr that the cells
were able to extrude without observable accumulation
over a 60 min period and susceptibility toward several
EIs. The results obtained clearly showed a distinct capa-
city of the two groups of isolates to extrude EtBr from
their cells, with the EtBrCW-positive isolates being able
to handle higher EtBr concentrations with no detectable
accumulation. It was also observed that for both groups
of isolates, EtBr extrusion/accumulation was most
affected by the EI verapamil.
Table 2 EP gene expression analysis by RT-qPCR of representative S. aureus exposed to CIP or EtBr
Overexpression levels* and no. of isolates** showing gene overexpression
½ CIP MIC ½ EtBr MIC
EtBrCW- EtBrCW+ EtBrCW- EtBrCW+
Gene ATCC25923 isolates isolates ATCC25923 isolates isolates
(n = 4) (n = 6) (n = 4) (n = 6)
norA - - - 4.51 ± 0.77 - -
00 00
norB 13.80 ± 6.50 5.43 ± 2.39 5.47 ± 0.19 7.07 ± 2.78 5.33 ± 0.73 -
2
a, b 1
e 1
a 0
norC - - 4.92 ± 0.00 5.89 ± 0.71 4.99 ± 1.51 -
0 1
e 1
a 0
mepA - - 8.59 ± 0.59 3.90 ± 0.13 5.94 ± 1.02 -
0 1
f 1
a 0
mdeA - 4.97 ± 0.68 - 3.96 ± 2.10 - 4.15 ± 1.12
1
c 00 1
d
smr n.a. n.a. - n.a. n.a. 7.66 ± 3.66
0 1
f
* Gene expression was measured in the presence of ciprofloxacin and EtBr relatively to the drug-free condition. The results are expressed in terms of the mean ±
standard deviation of at least three independent assays performed with independently extracted RNAs and correspond to the range of values obtained for
isolates showing overexpression of that gene. **The numbers in bold correspond to the number of isolates overexpressing that gene:
a isolate SM2;
b SM3;
c
SM5;
dSM25;
e SM50;
f SM52. Overexpression was considered for values ≥4 [10]. (-): no overexpression was detected; n.a.: not applicable.
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Page 6 of 12The efflux assays further demonstrated the higher
efflux capacity of the EtBrCW-positive isolates, with a
pronounced decreased of EtBr fluorescence (80%) within
a 2 min interval, whereas the EtBrCW-negative isolates
showed a smaller decrease ofE t B rf l u o r e s c e n c e( 4 0 % )
over a 10 min interval.
These results were then complemented with MIC
determination in the presence of EIs, leading to the
observation that the efflux-mediated resistance is an
important component of the level of fluoroquinolone
resistance. In fact, not only the 12 EtBrCW-positive iso-
lates presented higher MIC values towards the several
fluoroquinolones, also these MIC decreased to levels
similar to those of the EtBrCW-negative isolates in the
presence of TZ and CPZ, even for isolates sharing the
same QRDR mutations (Table 1). Altogether, these data
demonstrate that mutations in the QRDR of grlA and
gyrA genes confer resistance up to a certain level (8-32
mg/L for ciprofloxacin), above which resistance is
mainly efflux-driven. This implies that although the
inhibition of the efflux component by EIs does not bring
resistance down to the susceptibility level, it promotes a
significant decrease in this resistance.
In the MIC assays TZ and CPZ were the two EIs with
the highest effect, whereas in the fluorometric assay,
EtBr extrusion/accumulation was most affected by vera-
pamil. This should reflect differences in the mechanism
of action of each molecule, as well as to the characteris-
tics of each assay. We have recently observed the same
type of results with isolates of Mycobacterium smegmatis
[21]. The absence of efflux inhibitory effect of CCCP at
sub-MIC concentrations for S. aureus strains has been
discussed in a previous study [13].
For the analysis of gene expression, we first compared
our clinical isolates to a fully-antibiotic susceptible refer-
ence strain, S. aureus ATCC25923, following the ratio-
nale of previous studies, [10,20,22]. However, in contrast
to these earlier studies, no EP gene was found to be
overexpressed. Consequentially, we explored the effect
of exposing the isolates to ½ the MIC of the antimicro-
bial compounds used previously as selective markers,
ciprofloxacin and EtBr, using the isolates grown in a
drug-free condition as a reference for determining the
gene expression level. Using this approach, we were able
to detect overexpression of EP genes, albeit at levels
lower than the ranges described in literature [10,20,22].
These differences could, in some extent, reflect the dif-
ferent approaches used, including the use of a different
reference strain for gene expression assays. Nevertheless,
the different methodological approaches do not explain
all the results and since EtBrCW-positive isolates
showed a strong involvement of efflux in the resistance
phenotype, the absence of high levels of efflux pump
genes expression suggests that the isolates could be
already primed to respond to these noxious compounds.
Clinical isolates are under a constant pressure by anti-
microbial compounds, such as antibiotics and biocides.
Since the expression of efflux pumps provides the cell
with the means to cope with these compounds, it could
be expected that those clinical isolates already have in
their cell membrane the necessary number of efflux
pump proteins, thus, increases in efflux pump genes
expression may have already taken place. Also, no signif-
icant differentiation could be established between
EtBrCW-positive and EtBrCW-negative isolates at the
level of individual EP gene expression (Table 2). On the
other hand, ATCC25923, which showed only basal
efflux activity on the fluorometric assay, responded to
drug pressure in a completely different manner, showing
a significant overexpression of all efflux pump genes
t e s t e di nt h ep r e s e n c eo fE t B ra n dt h eh i g h e s te x p r e s -
sion level of norB following exposure to ciprofloxacin
(Table 2). The distinct behavior observed for the clinical
isolates as compared to the antibiotic fully susceptible
reference strain further support the hypothesis that the
clinical strains are primed to efflux noxious substances.
Increasing the concentration of ciprofloxacin to ¾ of
the MIC augmented the expression rate of the already
overexpressed genes with the additional overexpression
of other efflux pump genes. These results show a clear
concentration level above which there is an inducement
of expression of the same or additional efflux pump
genes. This response could reflect the involvement of
these genes in a global stress response regulon, or sim-
p l yb et h er e s u l to fas u b s t r a t e - r e s p o n s i v er e g u l a t i o n .
Future work should clarify this aspect.
A previous study described the predominance of norB
overexpression among a collection of S. aureus blood-
stream isolates. For this collection, when a single efflux
pump gene was overexpressed, it corresponded mostly
to norA,w h e r e a snorB and norC were prevalent when
two or more efflux pump genes were overexpressed
[10]. In our work, amongst the clinical isolates that
overexpressed efflux pump genes, four showed overex-
pression of a single gene, either norB, mdeA or mepA.
Only two isolates showed overexpression of more than
one efflux pump gene. Remarkably, norA was the only
gene for which no overexpression was detected among
the clinical isolates, suggesting that other efflux pumps
can have a more relevant role in the resistance to fluor-
oquinolones and EtBr in S. aureus than the one attribu-
ted to date. Nevertheless, exposure of ATCC25923 to
EtBr, resulted in the overexpression of all efflux pump
genes tested, including norA. This result does not
oppose to our previous finding that the prolonged expo-
sure of this strain to increasing concentrations of EtBr
resulted in high overexpression of solely norA [13], inas-
much as it strengthens the premise that exposure of the
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concentrations and/or time may result in the activation
of different efflux systems. Our data also revealed that
the same clinical isolate can respond differently at the
gene expression level, to thep r e s e n c eo ft w oi n d u c e r s ,
ciprofloxacin and ethidium bromide, both common sub-
strates of the main multidrug efflux pumps in S. aureus.
For example, the EtBrCW-negative isolate SM2 exposed
to ciprofloxacin showed only norB overexpression,
whilst in the presence of EtBr, it overexpressed norB,
norC and mepA. In the particular case of strain SM52,
the plasmid encoded Smr pump was only overexpressed
upon exposure to EtBr, whereas when challenged with
ciprofloxacin, the strain responded with the overexpres-
sion of mepA. Our data also demonstrates that isolates
from the same clone, as defined by PFGE, can have dis-
tinct levels of efflux activity and respond to the same
agent through the activation of different efflux pumps
(cf Tables 1 and 2).
Conclusions
The rationale and methodologies applied in this study
showed that efflux activity is an important component
of the resistance to fluoroquinolones and other com-
pounds in clinical isolates of S. aureus.W ed e m o n -
strated that not only different substrates can trigger
different pumps, but also that the same substrate can
promote a variable response, according to its concentra-
tion, thus strengthening the crucial role played by efflux
pumps in the survival of S. aureus clinical isolates in
health-care settings. Additionally, our study underlines
the importance of using new molecular approaches to
fully understand the function that each individual efflux
pump undertakes in the bacterial cell response to anti-
microbial compounds.
In particular, although specific clones could be found
among either EtBrCW-positive or EtBrCW-negative bac-
teria, isolates belonging to the same clonal type showed
different responses towards drug exposure, thus eviden-
cing that highly related clinical isolates, sharing the
same genetic background, may diverge in the efflux-
mediated response to noxious compounds. The data
gathered by the semi-automated fluorometric method
together with the results from the RT-qPCR assays, sus-
tain the hypothesis that S. aureus clinical isolates may
be primed to efflux antimicrobial compounds. There-
fore, the lack of a marked response to the induction of
efflux pump genes expression may be explained by the
higher efflux capacity already present in all the clinical
isolates tested, when compared to the naive reference
strain S. aureus ATCC25923.
Altogether, the results presented in this study show
the potential role played by efflux systems in the devel-
opment of resistance to fluoroquinolones in hospitals
and the contribution of the several S. aureus efflux sys-
tems to this resistance.
Methods
Bacterial isolates
Reference strains
S. aureus strain ATCC25923, a clinical isolate collected
at Seattle in 1945 and ATCC25923EtBr [13], belonging to
the culture collection of the Grupo de Micobactérias,
Unidade de Microbiologia Médica, Instituto de Higiene
e Medicina Tropical (IHMT/UNL), were used as
controls.
Clinical strains
Ac o l l e c t i o no f5 2S. aureus was studied, comprising all
the ciprofloxacin resistant clinical isolates sampled at
the Bacteriology Laboratory of a 1, 300-bed teaching
hospital (Lisbon, Portugal), from December 2006 to
March 2007. These corresponded to 49 MRSA and 3
MSSA, isolated from single patients and different biolo-
gical products. All isolates were tested for identification
and antibiotic susceptibility by the automated system
WalkAway
® (Dade Behring™) and selected on the basis
of their resistance to ciprofloxacin.
Growth conditions
Strains were grown in tryptic soy broth (TSB) at 37°C
with shaking or in tryptic soy agar (TSA) (Oxoid Ltd.,
Basingstoke, UK). Strain ATCC25923EtBr was grown in
TSB or TSA supplemented with 50 mg/L of EtBr. For
determination of minimum inhibitory concentrations
(MICs), cultures were grown in Mueller-Hinton broth
(MH, Oxoid) at 37°C.
Antibiotics and dyes
Antibiotics in powder form were purchased from differ-
ent sources, as follows: nalidixic acid (Sigma-Aldrich, St.
Louis, MO, USA); norfloxacin (ICN Biomedicals Inc.,
Ohio, USA); ciprofloxacin (Fluka Chemie GmbH, Buchs,
Switzerland). EtBr was acquired in powder form from
Sigma (Madrid, Spain).
Efflux inhibitors (EIs)
Carbonyl cyanide m-chlorophenylhydrazone (CCCP),
thioridazine (TZ), chlorpromazine (CPZ), verapamil
(VER) and reserpine (RES) were purchased from Sigma.
Solutions of TZ, CPZ and VER were prepared in desio-
nized water; RES was prepared in dimethylsulfoxide
(DMSO) and CCCP in 50% methanol (v/v). All solutions
were prepared on the day of the experiment and kept
protected from light.
EtBr-agar Cartwheel (EtBrCW) Method
This simple method tests the presence of active efflux
systems [11,12,23], being an update of the already
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vides information on the capacity of each isolate to
extrude EtBr from the cells by efflux pumps, on the
basis of the fluorescence emitted by cultures swabbed in
EtBr-containing agar plates. Briefly, each culture was
swabbed onto TSA plates containing EtBr concentra-
tions ranging from 0.5 to 2.5 mg/L (0.5 mg/L incre-
ments). S. aureus cultures ATCC25923 and
ATCC25923EtBr were used as negative and positive con-
trols for efflux activity, respectively [13]. The plates were
incubated at 37°C during 16 hours, after which the
minimum concentration of EtBr associated with the bac-
terial mass that produced fluorescence under UV light
was recorded in a Gel-Doc XR apparatus (Bio-Rad, Her-
cules, CA, USA). Isolates showing fluorescence at lower
EtBr concentrations have potentially less active efflux
systems than isolates for which fluorescence is only
detected at higher concentrations of EtBr [11,12,23,24].
Isolates showing emission of fluorescence only at the
maximum concentration of EtBr tested (2.5 mg/L) were
considered to have potential active efflux systems.
Drug susceptibility testing
Antibiotics and EtBr
MICs for antibiotics were determined by the two-fold
broth microdilution method [25]. Results were evaluated
according to the CLSI breakpoints [25], except for nali-
dixic acid, for which there are no defined breakpoints.
MICs for EtBr were also determined using the two-fold
broth microdilution method. After an 18 hour incuba-
tion period at 37°C, the MIC values were recorded, cor-
responding to the lowest concentration of EtBr that
presented no visible growth. All MICs were determined
in triplicate.
Efflux inhibitors (EIs)
Each EI employed in this study was evaluated for its
ability to reduce or reverse resistance to given antibio-
tics or EtBr, both of which are characteristics that define
the agent as an inhibitor of efflux pump activity [26].
The evaluation of an agent for EI activity was conducted
in medium containing varying concentrations of the
antibiotic or EtBr and a bacterial inoculum correspond-
ing to the one used for MIC determination. Parallel cul-
tures were tested in media containing no EI and EI (at
sub-lethal concentrations, see below) plus varying con-
centrations of the compound to be tested. The cultures
were incubated for 18 hours and growth evaluated
visually. An EI was considered to have an inhibitory
effect when a decrease of at least four-fold in the MIC
was observed in the presence of that EI, relatively to the
original MIC [10]. MICs of each EI were determined by
the two-fold broth microdilution method, as described
above. The final concentrations of the EIs used, which
correspond to half, or below, the MICs determined for
each EI, were: TZ (12.5 mg/L); CPZ (25 mg/L); VER
(200 mg/L); RES (20 mg/L) and CCCP (0.25 mg/L). All
assays were performed in triplicate.
Semi-automated fluorometric method
This method allows the real-time fluorometric detection
of the accumulation of a given efflux pump substrate (in
this case, EtBr) inside cells and its efflux, using a Rotor-
Gene 3000™ thermocycler, together with real-time ana-
lysis software (Corbett Research, Sydney, Australia)
[14,27,28]. Accumulation assays allow to assess the EtBr
concentration above which detectable EtBr accumulation
occurs and to select the most effective efflux inhibitor;
that is the EI that promotes the highest EtBr accumula-
tion [14]. These conditions can then be used to load
bacterial cells with EtBr and follow its efflux.
For the accumulation assays, the cultures were grown
in TSB medium at 37°C with shaking until they reach
an optical density at 600 nm (OD600 nm)o f0 . 6 .T op r e -
pare the cellular suspension, the cells were collected by
centrifugation at 13, 000 rpm for 3 minutes and the pel-
let washed twice with a 1X Phosphate Buffered Saline
(PBS) solution. The OD600 nm of the cellular suspension
was then adjusted to 0.6 in 1X PBS. To determine the
EtBr concentration where there is detectable accumula-
tion, several assays were prepared in 0.1 mL (final
volume) containing 0.05 mL of the cellular suspension
(final OD600 nm of 0.3) and 0.05 mL of 2X EtBr stock
solutions (final concentrations of 0.25, 0.5, 1, 2, 3, 4 and
5 mg/L). To determine the most effective EI, assays
were prepared in a final volume of 0.1 mL containing
0.05 mL of the cellular suspension (final OD600 nm 0.3)
and 0.05 mL of a solution containing 2X the EtBr con-
centration previously selected and 2X the EI concentra-
tion to be tested (final concentrations of TZ: 12.5 mg/L,
C P Z :2 5m g / L ,V E R :2 0 0m g / L ,R E S :2 0m g / L ) .A l l
assays included control tubes containing only the isolate
(0.05 mL of cellular suspension at OD600 nm of 0.6 plus
0.05 mL of 1X PBS) and only the EtBr concentration to
be tested (0.05 mL of 2X EtBr stock solution plus 0.05
mL of 1X PBS). The assays were then run in a Rotor-
Gene 3000™ at 37°C, and the fluorescence of EtBr was
measured (530/585 nm) at the end of every cycle of 60
seconds, for a total period of 60 minutes.
For the efflux assays, EtBr-loaded cells were prepared
by incubating a cellular suspension with an OD600 nm of
0.3 with either 0.25 or 1 mg/L EtBr for EtBrCW-nega-
tive or positive cultures, respectively and 200 mg/L VER
at 25°C for 60 minutes. After EtBr accumulation, cells
were collected by centrifugation and re-suspended in 1X
PBS to an OD600 nm of 0.6. Several parallel assays were
then run in 0.1 mL final volume corresponding to 0.05
mL of the EtBr loaded cells (final OD600 nm of 0.3) incu-
bated with 0.05 mL of (1) PBS 1X only; (2) glucose 0.8%
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(final concentration of 200 mg/L); (4) glucose 0.8% (final
concentration of 0.4%) plus 2X VER (final concentration
of 200 mg/L). These efflux assays were conducted in the
Rotor-Gene 3000™ at 37°C, and the fluorescence of
EtBr was measured (530/585 nm) at the end of every
cycle of 10 seconds, for a total period of 10 minutes.
The raw data obtained was then normalized against data
obtained from non-effluxing cells (cells from the control
tube with only 200 mg/L VER), at each point, consider-
ing that these correspond to the maximum fluorescence
values that can be obtained during the assay. The rela-
tive fluorescence thus corresponds to the ratio of fluor-
escence that remains per unit of time, relatively to the
EtBr-loaded cells.
Macrorestriction analysis
Isolates were typed by pulsed-field gel electrophoresis
(PFGE) analysis, using well-established protocols. Briefly,
agarose disks containing intact chromosomal DNA were
prepared as previously described [29] and restricted with
SmaI (New England Biolabs, Ipswich, MA, USA),
according to the manufacturer’s recommendations.
Restriction fragments were then resolved by PFGE,
which was carried out in a contour-clamped homoge-
neous electric field apparatus (CHEF-DRIII, Bio-Rad), as
previously described [29]. Lambda ladder DNA (New
England Biolabs) was used as molecular weight marker.
PFGE types were defined according to the criteria of
Tenover et al. [17].
Preparation of chromosomal DNA
Genomic DNA was extracted with the QIAamp DNA
Mini Kit (QIAGEN, Hilden, Germany), with an addi-
tional step of 30 minutes digestion with lysostaphin
(Sigma) (200 mg/L) prior to extraction.
Preparation of plasmid DNA
T h eQ I A p r e pS p i nM i n i p r e pk i t( Q I A G E N )w a su s e d ,
with the following modification: prior to extraction, cells
were incubated with lysostaphin (35 mg/L) at 37°C for
90 minutes, as previously described [30].
Screening of mutations in grlA and gyrA genes
Internal fragments comprising the QRDR of grlA and
gyrA genes were amplified using the primers described
in Table 3. The reaction mixture (50 μL) contained 2.5
Uo fTaq Polymerase (Fermentas Inc., Ontario,
Canada), 1X Taq buffer (Fermentas); 25 pmol of each
primer; 0.2 mM of dNTP and 1.75 mM of MgCl2.T h e
PCR reactions were conducted in a thermocycler Mas-
tercycler personal 5332 (Eppendorf AG, Hamburg,
Germany). The amplification conditions were as fol-
lows: DNA was denatured at 94°C for 4 minutes,
followed by 35 cycles of denaturation at 94°C for 30
seconds, annealing at 50°C for 30 seconds and exten-
sion at 72°C for 1 minute, followed by a step of final
extension at 72°C for 5 minutes. Amplification pro-
ducts were purified and sequenced in both strands
using the same set of primers. Sequences were ana-
lyzed and aligned using the freeware programs BioEdit
and ClustalW, respectively.
PCR amplification of efflux pump genes
DNA fragments internal to five chromosomal and two
plasmid encoded efflux pump genes were separately
amplified by PCR, using the primers described in Table
3. Reaction mixtures were prepared as described above.
Amplification conditions were as follows: DNA was
Table 3 Primers used in this study
Primer
a Sequence (5’-3’) Amplicon
Size (bp)
Reference
QacA/
B_Fw
GCTGCATTTATGACAATGTTTG 628 [30]
QacA/
B_Rv
AATCCCACCTACTAAAGCAG
Smr_Fw ATAAGTACTGAAGTTATTGGAAGT 285 [18]
Smr_Rv TTCCGAAAATGTTTAACGAAACTA
NorA_Fw TTCACCAAGCCATCAAAAAG 620 [32]
NorA_Rv CTTGCCTTTCTCCAGCAATA [13]
NorA_Fw TTCACCAAGCCATCAAAAAG 95 [32]
NorA_RT
(Rv)
CCATAAATCCACCAATCCC This study
NorB_Fw AGCGCGTTGTCTATCTTTCC 213 [13]
NorB_Rv GCAGGTGGTCTTGCTGATAA
NorC_Fw AATGGGTTCTAAGCGACCAA 216 [13]
NorC_Rv ATACCTGAAGCAACGCCAAC
MepA_Fw ATGTTGCTGCTGCTCTGTTC 718 [13]
MepA_Rv TCAACTGTCAAACGATCACG
MepA_RT
(Fw)
TGCTGCTGCTCTGTTCTTTA 198 [13]
MepA_RT
(Rv)
GCGAAGTTTCCATAATGTGC
MdeA_Fw AACGCGATACCAACCATTC 677 [13]
MdeA_Rv TTAGCACCAGCTATTGGACCT
MdeA_RT
(Fw)
GTTTATGCGATTCGAATGGTTGGT 155 [33]
MdeA_RT
(Rv)
AATTAATGCAGCTGTTCCGATAGA
16S_27f AGAGTTTGATCMTGGCTCAG 492 [34]
16S_519r GWATTACCGCGGCKGCTG
GrlA_Fw TGCCAGATGTTCGTGATGGT 339 [35]
GrlA_Rv TGGAATGAAAGAAACTGTCTC
GyrA_Fw TCGTGCATTGCCAGATGTTCG 394 [35]
GyrA_Rv TCGAGCAGGTAAGACTGACGG
aThe primers used in the RT-qPCR experiments are indicated by the RT label.
Fw: forward; Rv: reverse. For norB, norC and smr, the same set of primers was
used for both PCR and RT-qPCR, as well as the primer NorA_Fw.
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of denaturation at 94°C for 30 seconds, annealing at 45°
C( norA)o r5 3 ° C( norB, norC, mdeA, mepA)f o r3 0s e c -
onds and extension at 72°C for 1 minute, followed by a
step of final extension at 72°C for 5 minutes. The PCR
reactions for genes qacA/B and smr were conducted
under the following conditions: DNA was denatured at
95°C for 1 minute, followed by 30 cycles of denaturation
at 95°C each for 1 minute, annealing at 40°C (qacA/B)
or 48°C (smr) for 1 minute and extension at 72°C for 1
minute, followed by a step of final extension at 72°C for
5 minutes. The amplificationp r o d u c t sw e r ev i s u a l i z e d
by 1% agarose gel electrophoresis.
RNA extraction
For RNA extraction, strains were cultured in TSB media
containing ciprofloxacin or EtBr, at ½ their MIC for
each strain or in drug-free TSB, and grown until an
OD600 nm of 0.6. Total RNA was extracted with the
RNeasy Mini Kit (QIAGEN), following the manufac-
turer’s instructions. Before extraction of total RNA, cul-
tures were treated with the RNAprotect bacterial
reagent (QIAGEN). Contaminating DNA was removed
with RNase-free DNase (QIAGEN) by a two hours on-
column digestion at room temperature.
RT-qPCR protocol
Quantitative RT-PCR (RT-qPCR) was performed using
the QuantiTect SYBR Green RT-PCR Kit (QIAGEN).
The primers used in these assays are described in
Table 3. The relative quantity of mRNA correspond-
ing to genes norA, norB, norC, mepA, mdeA and smr
was determined by the comparative threshold cycle
(CT)m e t h o d[ 3 1 ]i naR o t o r - G e n e3 0 0 0 ™ thermocy-
cler with real-time analysis software. Relative expres-
sion of the efflux pump genes was assessed by two
approaches: (i) comparison of the relative quantity of
the respective mRNA in the S. aureus isolates to the
one present in a reference strain, ATCC25923; (ii)
comparison of the relative quantity of the respective
mRNA in the presence of ciprofloxacin or EtBr (at ½
the MIC) to the drug-free condition. For each strain,
three assays were conducted, corresponding to three
independent total RNA extractions. Negative controls
and genomic DNA contamination controls were
included. 16S rDNA was used as reference. Genes
showing increased expression of at least four-fold,
when compared to the drug-free condition, were con-
sidered to be overexpressed [10].
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